Anixa Biosciences (NASDAQ:ANIX) Downgraded to “Sell” Rating by Wall Street Zen
by Doug Wharley · The Cerbat GemWall Street Zen downgraded shares of Anixa Biosciences (NASDAQ:ANIX – Free Report) from a hold rating to a sell rating in a research report sent to investors on Saturday morning.
Other equities research analysts also recently issued research reports about the stock. D. Boral Capital reissued a “buy” rating and set a $10.00 price target on shares of Anixa Biosciences in a research report on Tuesday, March 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Anixa Biosciences in a research note on Monday, December 29th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $8.50.
Read Our Latest Stock Report on ANIX
Anixa Biosciences Price Performance
Shares of NASDAQ ANIX opened at $2.55 on Friday. Anixa Biosciences has a 1 year low of $2.33 and a 1 year high of $5.46. The stock has a market cap of $85.50 million, a P/E ratio of -7.73 and a beta of 0.57. The firm has a 50-day moving average of $2.85 and a 200 day moving average of $3.51.
Anixa Biosciences (NASDAQ:ANIX – Get Free Report) last announced its quarterly earnings data on Monday, March 9th. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01. Research analysts expect that Anixa Biosciences will post -0.41 earnings per share for the current fiscal year.
Insider Activity at Anixa Biosciences
In related news, Director Arnold M. Baskies acquired 10,000 shares of the firm’s stock in a transaction dated Wednesday, January 28th. The stock was purchased at an average cost of $3.04 per share, with a total value of $30,400.00. Following the completion of the acquisition, the director directly owned 135,000 shares of the company’s stock, valued at approximately $410,400. This trade represents a 8.00% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. 26.40% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Anixa Biosciences
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. NewEdge Advisors LLC bought a new stake in Anixa Biosciences in the 2nd quarter worth approximately $33,000. Cetera Investment Advisers purchased a new position in shares of Anixa Biosciences in the 4th quarter worth $35,000. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Anixa Biosciences by 2,000.0% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 10,500 shares of the company’s stock worth $35,000 after buying an additional 10,000 shares during the last quarter. Benjamin Edwards Inc. bought a new stake in shares of Anixa Biosciences in the second quarter worth $37,000. Finally, Millennium Management LLC bought a new stake in shares of Anixa Biosciences in the fourth quarter worth $38,000. Hedge funds and other institutional investors own 29.13% of the company’s stock.
Anixa Biosciences Company Profile
Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.
In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.